1-溴-4-乙氧基-2-(三氟甲基)苯 | 156605-95-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-溴-4-乙氧基-2-(三氟甲基)苯
• 英文名称: 4-bromo-1-ethoxy-3-trifluoromethyl-benzene
• 英文别名: 2-bromo-5-ethoxybenzotrifluoride；1-Bromo-4-ethoxy-2-(trifluoromethyl)benzene
• CAS: 156605-95-7
• 化学式: C₉H₈BrF₃O
• 分子量: 269.061
• InChiKey: SMBKTJHPNAJJOC-UHFFFAOYSA-N

物化性质

• 沸点：
  237.2±40.0 °C(Predicted)
• 密度：
  1.497±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2909309090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Bromo-4-ethoxy-2-(trifluoromethyl)benzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Bromo-4-ethoxy-2-(trifluoromethyl)benzene
CAS number: 156605-95-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H8BrF3O
Molecular weight: 269.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-溴-4-乙氧基-2-(三氟甲基)苯 、 硼酸三异丙酯 在 正丁基锂 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 反应 0.58h， 生成
  参考文献：
  名称：

  6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives

  摘要：

  本发明涉及具有通式I的6-苯基-1H-咪唑[4,5-c]吡啶-4-碳腈衍生物，其中每个取代基的定义如规范和权利要求中所述，包括含有这些衍生物的药物组合物，以及利用这些衍生物制备用于治疗与cathepsin S和/或cathepsin K相关疾病的药物，如骨质疏松症、动脉粥样硬化、炎症和免疫紊乱，如类风湿性关节炎，以及慢性疼痛，如神经病理性疼痛。

  公开号：

  US20070179138A1
• 作为产物：
  描述：

  2-氘代苯甲酸甲酯 在 溴 作用下， 以 水 为溶剂， 生成 1-溴-4-乙氧基-2-(三氟甲基)苯
  参考文献：
  名称：

  Liquid crystalline compound, liquid crystal composition and their polymers

  摘要：

  本发明提供了一种由规范中定义的式（1）表示的化合物和包含该化合物的液晶组合物。本发明进一步提供了由上述化合物或组合物聚合获得的聚合物，以及本发明提供了使用该聚合物的薄膜、光学各向异性材料、1/4或1/2波长功能板、光学补偿元件、光学元件和液晶显示元件。

  公开号：

  US07070838B2

文献信息

• PROCESS FOR THE PREPARATION OF PROLINE DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130123512A1

  公开（公告）日：2013-05-16

  The present invention relates in part to a process for the preparation of a proline derivative of formula I wherein, R 1 is C 1-7 -alkyl or wherein R 4 is selected from the group consisting of C 1-7 -alkyl, halogen-C 1-7 -alkyl and phenyl optionally substituted by halogen; R 2 is halogen or halogen-C 1-7 -alkyl; and R 3 is selected from the group consisting of hydrogen, halogen, halogen-C 1-7 -alkyl, C 1-7 -alkoxy, halogen-C 1-7 -alkoxy and a 5- or 6-membered heterocyclic ring containing one or two nitrogen atoms, said ring being optionally substituted by C 1-7 -alkyl or halogen. The proline derivatives of the formula I are preferential inhibitors of the cysteine protease Cathepsin S and are therefore useful to treat metabolic diseases like diabetes, atherosclerosis, abdominal aortic aneurysm, peripheral arterial disease and diabetic nephropathy.

  本发明部分涉及一种制备式I的脯氨酸衍生物的过程 其中， R 1 为C 1-7 -烷基或 其中R 4 选自由C 1-7 -烷基、卤代C 1-7 -烷基和苯基（可选择地被卤素取代）的群组; R 2 为卤素或卤代C 1-7 -烷基; 以及 R 3 选自由氢、卤素、卤代C 1-7 -烷基、C 1-7 -烷氧基、卤代C 1-7 -烷氧基和含有一个或两个氮原子的5-或6-成员杂环环，该环可选择地被C 1-7 -烷基或卤素取代。 式I的脯氨酸衍生物是优选的半胱氨酸蛋白酶S的抑制剂，因此可用于治疗代谢性疾病，如糖尿病、动脉粥样硬化、腹主动脉瘤、外周动脉疾病和糖尿病肾病。
• 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
  申请人：N.V. Organon

  公开号：US07687515B2

  公开（公告）日：2010-03-30

  The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula I wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.

  本发明涉及具有一般式I的6-苯基-1H-咪唑[4,5-c]吡啶-4-碳腈衍生物，其中每个取代基的定义如规范和权利要求中所述，以及包含它们的制药组合物，以及利用这些衍生物制备治疗与cathepsin S和/或cathepsin K相关的疾病，如骨质疏松症、动脉粥样硬化、炎症和免疫紊乱，如类风湿性关节炎和慢性疼痛，如神经病理性疼痛的药物的用途。
• 6-PHENYL-1H-IMIDAZO[4, 5-C]PYRIDINE-4-CARBONITRILE DERIVATIVES AS CATHEPSIN K AND S INHIBITORS
  申请人：N.V. Organon

  公开号：EP1979351A1

  公开（公告）日：2008-10-15
• US7070838B2
  申请人：——

  公开号：US7070838B2

  公开（公告）日：2006-07-04
• US7687515B2
  申请人：——

  公开号：US7687515B2

  公开（公告）日：2010-03-30